| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 topline data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Renal/Genitourinary System | ||
Phase 1 topline data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Renal/Genitourinary System | ||
Phase 1 topline data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Renal/Genitourinary System |
Recent Updates
Recently added Catalysts
SCYNEXIS, Inc.$4.38
-0.19 (-4.05%)
C 41Pipeline Score Undervalued Pharma · Clinical
Market Cap
58.10 M
EPS
-0.45
P/E Ratio
-
Value Trade
323.96 K
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
12.35 M
Operating CF
-8.10 M
Total Assets
77.63 M
Total Liabilities
36.32 M
Equity
41.31 M
D/E Ratio
12,345
-5.03 %
Week
-31.01 %
1 Month
-9.72 %
3 Month
1.57 %
6 Month
-91.23 %
5 Year
-99.25 %
All Time
Cash Data
Cash Position
59.26 M
Monthly Burn
2.70 M
Runway
20.1 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
111.47 K
52 Week Range
0.57 - 1.31
% held by Insiders
3.91 %
% held by Institutions
38.54 %
Enterprise Value
814.40 K
Total Shares
44.67 M
Short %
0.9 %
Float Shares
42.44 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for SCYNEXIS, Inc.
631Total events
12Upcoming
149Tier-1 (high impact)
2010 – 2035Coverage
Upcoming catalysts 12
Event history 619
Q3 2026
◆Topline ReadoutSCY-770Clinical Data
Topline data from Phase 1 study expected
Autosomal Dominant Polycystic Kidney Disease (ADPKD)source ↗
Q3 2026
◆Topline ReadoutSCY-247Clinical Data
Topline data from Phase 1 IV formulation study expected
antifungalsource ↗
Jun 30, 2026
▲Trial InitiationSCY-770Trial
Phase 1 study of SCY-770 initiated
Autosomal Dominant Polycystic Kidney Disease (ADPKD)source ↗
May 29, 2026
Apr 2026
Mar 31, 2026
Mar 31, 2026
▼Equity OfferingCorporate
Announced $40.0 million private placement with potential additional $52.2 million from warrant exercise
Mar 31, 2026
◆AcquisitionPXL-770Corporate
SCYNEXIS acquires PXL-770 (now SCY-770) from Poxel S.A.
Autosomal Dominant Polycystic Kidney Disease (ADPKD)source ↗
Drug Pipeline Intelligence
C41
Pipeline Score $189M
Pipeline ValueUndervalued
Valuation Signal5
Drugs Scored3.3x
rNPV / MCap Top 59%
Micro Cap (rank 375 of 911)
Percentile RankSCYNEXIS, Inc. carries a moderate pipeline score (41/100), with $2.2B risk-adjusted pipeline value, led by Ibrexafungerp in Invasive Candidiasis (Phase 3), across $73B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ibrexafungerp Small molecule | Vulvovaginal Candidiasis | Phase 3 | NCT06954493 | 50% | $1.5B | COMPLETED | 155 | - | - | Nov 1, 2023 | - | Aug 8, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SCY-247 Fast TrackOrphan | invasive fungal infections | Phase 1 | 2025-09-30 | tolerability: well tolerated across all evaluated SAD and MAD cohorts; adverse events: headache 16.7% of participants receiving SCY-247 and 4.5% of participants receiving placebo, diarrhea 9% of participants receiving SCY-247 and 9% of participants receiving placebo; participants: total 66, placebo 22; doses: SAD 50mg to 900mg, MAD 50mg to 300mg; pharmacokinetics: dose-proportional pharmacokinetics following single and multiple oral doses; Tmax: ranging from 3 to 7 hours Read More | SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247) Read More | |
SCY-247 Fast TrackOrphan | invasive fungal infections | Phase 1 | 2025-09-30 | tolerability: well tolerated across all evaluated SAD and MAD cohorts; adverse events: headache 16.7% of participants receiving SCY-247 and 4.5% of participants receiving placebo, diarrhea 9% of participants receiving SCY-247 and 9% of participants receiving placebo; participants: total 66, placebo 22; doses: SAD 50mg to 900mg, MAD 50mg to 300mg; pharmacokinetics: dose-proportional pharmacokinetics following single and multiple oral doses; Tmax: ranging from 3 to 7 hours Read More | SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247) Read More | |
SCY-247 Fast TrackOrphan | invasive fungal infections | Phase 1 | 2025-09-30 | tolerability: well tolerated across all evaluated SAD and MAD cohorts; adverse events: headache 16.7% of participants receiving SCY-247 and 4.5% of participants receiving placebo, diarrhea 9% of participants receiving SCY-247 and 9% of participants receiving placebo; participants: total 66, placebo 22; doses: SAD 50mg to 900mg, MAD 50mg to 300mg; pharmacokinetics: dose-proportional pharmacokinetics following single and multiple oral doses; Tmax: ranging from 3 to 7 hours Read More | SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247) Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SCYX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SCYX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SCYX▲ +5.2%on this news· ran to +22% by day 3
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SCYNEXIS, Inc. has initiated a Phase 1 study of SCY-770, a novel AMPK activator aimed at treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). The study will assess food effects and pharmacokinetics to inform dosing for a subsequent Phase 2 trial expected to start in Q4 2026. SCY-770 has shown promising preclinical results and has received Orphan Drug Designation from the FDA.
Read more →SCYX▼ -6.9%on this news
SCYNEXIS Announces One-for-Eight Reverse Stock Split - May 22, 2026
SCYNEXIS, Inc. announced a 1-for-8 reverse stock split effective May 29, 2026, to comply with Nasdaq listing requirements. The adjusted common stock will begin trading on June 1, 2026. The move aims to reduce the number of outstanding shares and enhance the company's market position. Stockholders will receive cash for any fractional shares.
Read more →SCYXSCYNEXIS Announces One-for-Eight Reverse Stock Split
SCYNEXIS, Inc. announced a 1-for-8 reverse stock split effective May 29, 2026. This action, approved by stockholders, aims to meet Nasdaq's minimum bid price requirement. Following the split, the number of authorized shares will decrease significantly, and stockholders will be compensated for any fractional shares in cash. The company's shares will start trading on June 1, 2026, under the existing symbol 'SCYX'.
Read more →SCYX▼ -10%on this news
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
SCYNEXIS, Inc. reported strong first-quarter 2026 financial results, including a successful acquisition of SCY-770, a drug for autosomal dominant polycystic kidney disease (ADPKD). The company aims to commence a Phase 2 study for SCY-770 in Q4 2026, with early efficacy results expected by late 2027. Additionally, SCYNEXIS secured $37.2 million in a private placement, extending its financial runway to mid-2029. Progress is also being made on the antifungal drug SCY-247, with topline data anticipated later this year.
Read more →SCYXSCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SCYNEXIS, Inc. announced the approval of inducement equity awards for a new Vice President as part of their strategy to attract talent. The awards, consisting of stock options and restricted stock units, are intended to incentivize the new employee's acceptance of the position. This move aligns with the company's ongoing commitment to developing innovative therapies, particularly for rare diseases like Autosomal Dominant Polycystic Kidney Disease.
Read more →SCYX▲ +16.1%on this news
Advancing innovative solutions for severe rare diseases Corporate Deck March 2026 Legal Disclaimers This presentation has been prepared by SCYNEXIS, Inc. (the "Company") solely for informational purposes. This presentati
SCYNEXIS, Inc. has presented a corporate deck outlining its strategies for addressing severe rare diseases, specifically focusing on its product candidates SCY-770 and SCY-247. The company reported successful financing of $40M, strengthening its cash position and enabling the initiation of Phase 2 studies for SCY-770. This product targets Autosomal Dominant Polycystic Kidney Disease (ADPKD), a condition with a significant unmet medical need. Notably, the anticipated partnership with GSK on BREXAFEMME could lead to substantial sales milestones. However, risks associated with the company's forward-looking statements have been highlighted, emphasizing the uncertainties inherent in drug development.
Read more →SCYX▲ +16.1%on this news
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PXL-770 (now SCY-770) is a clinic
SCYNEXIS, Inc. has completed the acquisition of PXL-770, now named SCY-770, a selective AMPK activator developed for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). This oral therapy aims to reduce cyst growth and has shown a favorable safety profile in clinical trials. With the anticipated launch of a Phase 2 study in Q4 2026, SCYNEXIS aims to address a significant unmet need in the ADPKD patient population. The acquisition includes an upfront payment, as well as potential milestone payments dependent on development progress.
Read more →SCYX▲ +16.1%on this news
SCYNEXIS Announces $40.0 million Private Placement
SCYNEXIS, Inc. has announced a $40 million private placement involving new and existing investors to fund ongoing operations and development of its therapies, particularly SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The agreement includes provisions for issuing common shares and warrants, potentially raising an additional $52.2 million if exercised. The closing of the deal is set for around April 1, 2026, but is contingent on certain closing conditions, including stockholder approval. The company aims to use the proceeds for working capital and has a projection of funding operations into mid-2029.
Read more →SCYX▲ +16.1%on this news
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
Poxel SA has announced a definitive agreement to sell PXL770 to Scynexis for up to $196 million. This deal is expected to bolster Poxel's financial position and support its ongoing development of treatments for metabolic diseases. The collaboration highlights the potential of PXL770 in addressing serious chronic conditions.
Read more →SCYXSCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
SCYNEXIS, Inc. reported its financial results for 2025, highlighting a significant increase in revenue primarily from a license agreement with GSK. The company is advancing its second-generation antifungal drug, SCY-247, and has secured a cash runway of over two years. Despite a decrease in total other income and cash balance, SCYNEXIS remains optimistic about future developments.
Read more →SCYXSCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
SCYNEXIS has announced the dosing of the first participants in a Phase 1 trial for SCY-247, an intravenous antifungal therapy aimed at treating invasive candidiasis. The drug has received both Qualified Infectious Disease Product and Fast Track designations from the FDA, highlighting its potential in addressing drug-resistant infections. Results from the trial are anticipated in 2026, following positive data from previous oral formulation studies.
Read more →SCYXSCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
SCYNEXIS, Inc. announced presentations on its second-generation fungicide, SCY-247, at the inaugural IMARI meeting in Las Vegas. The company emphasizes SCY-247's strong antifungal activity against resistant strains and its promising safety profile. The presentations will showcase the drug's potential role in combating deadly fungal infections, particularly those resistant to current treatments.
Read more →SCYXSCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
SCYNEXIS announced that it will present data on its second-generation fungicide SCY-247 at the inaugural IMARI meeting in Las Vegas. The presentations will highlight SCY-247's effectiveness against drug-resistant fungi and its favorable safety profile. The conference aims to address the growing threat of antimicrobial resistance, making this presentation timely and relevant.
Read more →SCYXSCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
SCYNEXIS has received FDA Qualified Infectious Disease Product and Fast Track designations for SCY-247, a novel antifungal therapy. This designation ensures market exclusivity for at least 10 years following approval. The drug has shown effectiveness against multi-drug resistant fungal infections, including Candida auris. SCYNEXIS plans to initiate Phase 1 and Phase 2 studies for SCY-247 in 2026.
Read more →SCYXSCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
SCYNEXIS, Inc. has been granted an additional 180-day extension by Nasdaq to meet the minimum bid price requirement for its shares. The company aims to utilize this time to advance its strategic goals, including completing a Phase 1 study and generating Phase 2 data for its investigational antifungal SCY-247. The extension allows SCYNEXIS to maintain its listing while working towards compliance.
Read more →SCYXSCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
SCYNEXIS has successfully transferred the New Drug Application for BREXAFEMME to GSK, enabling GSK to engage with the FDA regarding the drug's relaunch for vulvovaginal candidiasis. This milestone is expected to provide SCYNEXIS with future non-dilutive capital through sales milestones and royalties. The company continues to develop innovative antifungal therapies.
Read more →SCYXScynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
SCYNEXIS announced federal funding for a collaboration between Hackensack Meridian CDI and Johns Hopkins to develop new antifungal therapeutics. The initiative, supported by a $7 million annual grant from NIH, focuses on next-generation fungers to combat resistant fungal infections. This partnership aims to progress these candidates from preclinical stages to IND-ready status.
Read more →SCYX▼ -5.5%on this news
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
SCYNEXIS reported its third quarter 2025 financial results, highlighting significant achievements including positive data for its drug candidate SCY-247 and a resolution with GSK that brings in $24.8 million. The company anticipates a cash runway exceeding two years, supporting ongoing development efforts. However, they reported an increased net loss compared to the previous year.
Read more →SCYXSCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
SCYNEXIS has resolved its disagreement with GSK concerning the Phase 3 MARIO study, which will not proceed. As part of this resolution, SCYNEXIS will receive a $22 million payment from GSK and an additional $2.3 million for wind-down activities. Despite the setback with the MARIO study, GSK is committed to collaborating with SCYNEXIS on the commercialization of BREXAFEMME.
Read more →SCYX▼ -26.7%on this news
SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)
SCYNEXIS announced positive results from a Phase 1 study of SCY-247, its second-generation antifungal. The study showed that SCY-247 was well tolerated and achieved target exposures for efficacy at lower doses than its predecessor. The drug's favorable pharmacokinetics and safety profile support its continued development for treating invasive fungal infections.
Read more →SCYXSCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
SCYNEXIS, Inc. announced multiple presentations at the TIMM-12 Congress, showcasing data on its second-generation fungicide SCY-247. The presentations emphasize SCY-247's potential to combat difficult-to-treat and drug-resistant Candidainfections, including C. auris. The company plans to report results from its Phase 1 SAD/MAD trial of SCY-247 later this quarter.
Read more →SCYXSCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
SCYNEXIS, Inc. will participate in the H.C. Wainwright 27th Annual Global Conference from September 8 to 10, 2025. The senior leadership team will present in-person and hold one-on-one meetings. The company is known for its innovative antifungal treatments, including the FDA-approved BREXAFEMME, and is actively developing additional antifungal therapies.
Read more →SCYXSCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
SCYNEXIS, Inc. reported its second quarter 2025 financial results, highlighting the dosing of the first new patient in the Phase 3 MARIO study, which follows the lifting of a clinical hold by the FDA. The company anticipates a $10 million milestone payment from GSK, though disputes over milestone payments persist. Financially, SCYNEXIS ended the quarter with $46.5 million and projects a cash runway into Q4 2026. The company also prepares to transfer the BREXAFEMME NDA to GSK by the end of 2025, with regulatory discussions expected in 2026.
Read more →SCYX▲ +28%on this news
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
SCYNEXIS has resumed patient dosing in the Phase 3 MARIO study for ibrexafungerp, an oral antifungal therapy for invasive candidiasis. The study was previously halted due to FDA concerns but has now restarted following the manufacture of new clinical supplies. SCYNEXIS expects milestone payments from GSK contingent on the study's progress, despite ongoing disagreements regarding these payments.
Read more →SCYXSCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
SCYNEXIS reported its financial results for the first quarter of 2025, highlighting the lifting of the FDA clinical hold on its drug ibrexafungerp and progress in its MARIO study, despite facing a dispute with GSK regarding the study's future. The company presented encouraging preclinical data for its second-generation fungicidal candidate, SCY-247, and anticipates results from its Phase 1 study in late 2025. Financially, SCYNEXIS ended the quarter with $53.8 million, although it reported a net loss, contrasting with the previous year's profit.
Read more →SCYXSCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
SCYNEXIS, Inc. announced the presentation of preclinical data for SCY-247 at ESCMID 2025. This second-generation antifungal aims to combat systemic fungal diseases, particularly those resistant to current treatments. The data highlights SCY-247's efficacy against multidrug-resistant fungi, showcasing its potential as a significant advancement in antifungal therapy.
Read more →SCYXSCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
SCYNEXIS, Inc. reported its financial results for the year ending December 31, 2024, showcasing advancements in its drug development programs, particularly for SCY-247. The company is addressing the clinical hold on its Phase 3 MARIO study, anticipating a restart in Q2 of 2025. SCY-247, a second-generation antifungal, has shown promising results in preclinical studies and is set to advance further in clinical trials. However, SCYNEXIS recorded a net loss for the year and a decrease in revenue associated with its licensing activities.
Read more →SCYX▼ -9%on this news
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
SCYNEXIS, Inc. has commenced dosing in its Phase 1 trial for SCY-247, a novel antifungal candidate designed to treat invasive fungal infections. This study will assess the safety and tolerability of SCY-247 along with its pharmacokinetics. Preclinical data has shown that SCY-247 possesses broad-spectrum antifungal activity, particularly against drug-resistant pathogens. The company anticipates possible FDA designations that could expedite SCY-247's development due to the critical need for effective antifungal treatments.
Read more →SCYXSCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
SCYNEXIS, Inc. reported strong third quarter 2024 results, including a $10 million milestone payment triggered by the delivery of trial reports to GSK. The company's preclinical antifungal candidate, SCY-247, continues to show promising activity and is set to initiate Phase 1 studies by the end of Q4 2024. Despite an expected cash runway into Q3 2026, the company reported an increased net loss compared to the previous year, emphasizing the ongoing costs associated with research and development efforts. SCYNEXIS will participate in a healthcare conference, aiming to connect with investors and showcase its advances.
Read more →SCYXSCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
SCYNEXIS, Inc. (NASDAQ: SCYX) announced that its President and CEO, David Angulo, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on October 17. The company continues to develop its antifungal platform, particularly focusing on ibrexafungerp, which has received FDA approval for specific indications. This participation at the summit underscores SCYNEXIS's commitment to addressing difficult-to-treat infections and enhancing investor engagement.
Read more →SCYXSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
SCYNEXIS, Inc. announced that it will present preclinical data on its second-generation antifungal candidate SCY-247 at IDWeek 2024 in Los Angeles. The presentations will highlight the drug's efficacy and pharmacokinetic profile across various models of invasive fungal infections. SCY-247 is being developed to combat antimicrobial resistance and is anticipated to receive regulatory support from the FDA, which could expedite its development process. Currently in pre-IND development, SCY-247 shows promising broad-spectrum antifungal activity.
Read more →SCYXA dynamic force in the fight against infectious disease September 2024 Forward-Looking Statement Certain statements regarding SCYNEXIS, Inc. (the “Company”) made in this presentation constitute forward-look
SCYNEXIS, Inc. provided an update on its progress in combating infectious diseases, highlighting positive pre-clinical results for its antifungal drug SCY-247 and completion of key studies leading to a development milestone payment from GSK. The company outlined potential opportunities for growth in light of increasing public health concerns due to antifungal resistance. However, the presentation also emphasized risks related to market acceptance of its products and the requirements for continued funding and regulatory approvals.
Read more →SCYX▼ -5.7%on this news
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
SCYNEXIS, Inc. (NASDAQ: SCYX) will participate in the H. C. Wainwright 26th Annual Global Investment Conference on September 11, 2024. David Angulo, the CEO, will present and host one-on-one meetings during the event. The company focuses on developing innovative antifungal treatments to combat drug-resistant infections, with its product ibrexafungerp already approved by the FDA for treating vulvovaginal candidiasis and reducing recurrent cases. Ongoing investigations aim to explore further applications of the drug for serious fungal infections in hospitalized patients.
Read more →SCYXSCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update
SCYNEXIS, Inc. reported its financial results for Q2 2024, achieving a $10 million milestone payment due to the completion of key clinical trials. The company also highlighted positive preclinical results for SCY-247, its next-generation antifungal, with Phase 1 study initiation anticipated by Q4 2024. Despite ending the quarter with over $83 million in cash, SCYNEXIS recorded a net loss of $14.5 million, reflecting a significant drop in revenue compared to the previous year amid ongoing development of its antifungal therapies.
Read more →SCYXSCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports
SCYNEXIS, Inc. has announced it will receive a $10 million milestone payment from GSK following the completion of several clinical study reports for ibrexafungerp, aimed at treating invasive fungal infections. The company reported positive results from its trials and is set to resume the Phase 3 MARIO study. Additionally, SCYNEXIS maintains a robust financial outlook, with a cash runway surpassing two years, and plans to advance another antifungal candidate, SCY-247, into the clinic later this year. Overall, the agreement underscores SCYNEXIS's promising position in developing solutions for drug-resistant infections.
Read more →SCYXSCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
SCYNEXIS, Inc. reported its financial results for Q1 2024, highlighting its progress in developing SCY-247, a promising antifungal compound that targets drug-resistant infections. The company anticipates initiating a Phase I trial for SCY-247 later in 2024 and is on track to deliver clinical study reports for several trials that may unlock a $10 million milestone payment. As of March 31, 2024, SCYNEXIS had a strong cash position of $94.2 million, ensuring over two years of operational support, despite facing a clinical hold on ibrexafungerp due to contamination issues.
Read more →SCYX▼ -7.1%on this news
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
SCYNEXIS, Inc. presented promising preclinical data for its antifungal candidate SCY-247 at the ESCMID Global 2024 congress. The data revealed that SCY-247 was effective in reducing fungal burden in a mouse model of invasive candidiasis caused by Candida glabrata. Additionally, in vitro testing indicated that SCY-247 exhibited strong activity against a range of pathogenic fungi, including azole-resistant strains. The company is optimistic about SCY-247's potential as a treatment for difficult-to-treat fungal infections and plans to enter clinical trials by the end of the year.
Read more →SCYXSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
SCYNEXIS, Inc. announced the upcoming presentation of preclinical data on its antifungal drug candidate SCY-247 at the ECCMID 2024 in Barcelona. The compound targets severe fungal infections, particularly those caused by resistant strains like Candida auris and Candida glabrata. Early studies indicate that SCY-247 exhibits significant in vivo and in vitro efficacy, suggesting it could fill a critical gap in treatment options. The company also anticipates possible FDA designations that could enhance its development trajectory.
Read more →SCYXSCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update • SCY-247's IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 • Da
SCYNEXIS, Inc. reported its financial results for 2023, highlighting significant progress in developing its antifungal compound, SCY-247, which is expected to enter Phase I trials in late 2024. The company noted positive outcomes from its CARES study and anticipates the delivery of clinical study reports that may trigger milestone payments. Despite a solid cash position, revenue from its product, BREXAFEMME, declined, and certain impairment losses were reported due to potential contamination issues. Overall, SCYNEXIS remains focused on advancing its development pipeline and addressing emerging fungal infections.
Read more →SCYXSCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
SCYNEXIS, Inc. announced that its President and CEO, David Angulo, will present at Guggenheim's 6th Annual Biotechnology Conference on February 7, 2024. The company is focused on developing novel antifungal therapies, including ibrexafungerp, which has already been approved by the FDA for specific indications. The ongoing clinical investigations aim to address life-threatening invasive fungal infections. This engagement at a prominent biotech conference further underscores SCYNEXIS's commitment to innovation in drug-resistant infections.
Read more →SCYXSCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
SCYNEXIS, Inc. presented promising preclinical data on its second-generation antifungal SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference. The data showed that SCY-247, when administered orally, achieved significant survival rates in a lethal mouse model of mucormycosis, comparable to Liposomal Amphotericin B. Additionally, a combination therapy of SCY-247 and Liposomal Amphotericin B resulted in even greater survival and reduction in fungal burden, indicating its potential as a significant advancement in treating this life-threatening condition.
Read more →SCYX▲ +6.9%on this news
SCYNEXIS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against SCYNEXIS, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has initiated a class action lawsuit against SCYNEXIS, Inc. for allegedly providing misleading information about their manufacturing processes. This follows a report of potential cross-contamination in the drug ibrexafungerp, leading to a recall and suspension of clinical studies. The lawsuit seeks to represent investors who purchased SCYNEXIS securities during the specified class period, raising concerns over the company's operational integrity and transparency. The stock has seen significant declines following the revelations.
Read more →SCYXA dynamic force in the fight against infectious disease January 2024 Forward-Looking Statement Certain statements regarding SCYNEXIS, Inc. (the “Company”) made in this presentation constitute forward-lookin
SCYNEXIS, Inc. is moving forward with its efforts against infectious diseases, particularly through the development of SCY-247, a next-generation fungerp. The company has achieved key milestones, including financial support from GSK and promising pre-clinical data that will be shared at an upcoming conference. However, SCYNEXIS faces specific risks such as potential market acceptance issues for its drug BREXAFEMME and uncertainties associated with FDA approval processes. The company has a robust cash reserve, allowing it sufficient runway to pursue its development goals in antifungal treatments.
Read more →SCYXSCYNEXIS SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP is investigating potential claims against SCYNEXIS, Inc. due to allegations of false or misleading statements related to the manufacturing of ibrexafungerp. The firm is reminding investors of the January 8, 2024, deadline to seek the role of lead plaintiff in a federal securities class action. The complaint highlights issues such as cross-contamination risks and inadequate internal controls, leading to a recall of the drug and a halt on clinical studies. Subsequently, SCYNEXIS's stock experienced a substantial decline in value following the news.
Read more →SCYXSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
SCYNEXIS, Inc. has announced the presentation of preclinical data for SCY-247, a second-generation fungicide, at the upcoming AAAM Conference in Milan. In a neutropenic mouse model, SCY-247 demonstrated efficacy against pulmonary mucormycosis, matching the performance of currently used antifungals. Notably, its combination with liposomal amphotericin B resulted in improved survival rates compared to monotherapy. The company is moving towards clinical trials by the end of the year, reflecting a significant step in addressing drug-resistant fungal infections.
Read more →SCYXSCYNEXIS SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP is investigating potential claims against SCYNEXIS, Inc. following significant losses for investors due to alleged violations of federal securities laws. The complaint accuses the company of failing to disclose risks related to cross-contamination in its manufacturing process, resulting in a product recall and suspension of clinical studies. Following these revelations, SCYNEXIS's stock price saw a drastic decline, prompting the law firm to encourage affected investors to explore their legal options.
Read more →SCYXSCYNEXIS ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against SCYNEXIS, Inc. and Encourages Investors to Contact the Firm
A class action lawsuit has been initiated against SCYNEXIS, Inc. following a significant drop in its stock price due to a recall of its ibrexafungerp product. The lawsuit accuses the company of making misleading statements regarding its manufacturing practices that may have led to potential contamination risks. This follows the company's earlier announcement about halting clinical studies and recalling their product due to concerns with beta-lactam contaminants in the manufacturing process. Investors have until January 8, 2024, to claim their participation in the lawsuit seeking redress for financial losses incurred.
Read more →SCYX▲ +11.8%on this newsshared move
SCYNEXIS ONGOING DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP is investigating potential claims against SCYNEXIS, Inc. due to alleged violations of federal securities laws. The claims include accusations of misleading statements concerning the manufacturing processes of ibrexafungerp, which may pose a contamination risk. Following a market disclosure on September 25, 2023, regarding this risk, SCYNEXIS experienced a sharp decline in stock price, leading to increased scrutiny from investors. The firm urges affected investors to discuss their legal rights and the upcoming lead plaintiff deadline in a federal class action case.
Read more →SCYXSCYNEXIS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP is investigating claims against SCYNEXIS, Inc. regarding potential violations of federal securities laws. The firm highlights a class action lawsuit with a lead plaintiff deadline of January 8, 2024, for investors who incurred significant losses. The investigation stems from the discovery of cross-contamination risks in the manufacturing process of the drug ibrexafungerp, leading to a recall and suspension of clinical studies. Following these announcements, SCYNEXIS's shares experienced a notable decline in value.
Read more →SCYXSCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
SCYNEXIS reported its third quarter 2023 financial results, highlighting ongoing challenges including a voluntary recall of BREXAFEMME and a clinical hold on the MARIO study. Despite these setbacks, the company maintains a strong cash position of $105.2 million, projected to support operations for over two years. Development efforts for SCY-247, a next-generation antifungal, continue to make progress, and there are positive regulatory updates regarding ibrexafungerp in China. However, the financial impact of the recall has been significant.
Read more →SCYXSCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)
SCYNEXIS, Inc. announced the presentation of preclinical data on SCY-247, its second-generation antifungal candidate, at the 11th Congress on Trends in Medical Mycology. The data reveals SCY-247's potent in vitro activity against a broad range of fungal pathogens, including drug-resistant strains. Its favorable tissue distribution, including brain penetration, indicates potential for effective treatment of systemic fungal infections. Clinical studies for SCY-247 are planned to begin in the second half of 2024.
Read more →SCYX▲ +6.1%on this news
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece
SCYNEXIS, Inc. (NASDAQ: SCYX) has announced the upcoming presentation of preclinical data for its second-generation antifungal candidate SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) in Athens, Greece, from October 20-23, 2023. The data highlights SCY-247's efficacy against a range of fungal pathogens, including those resistant to existing treatments. The company also notes that it is seeking FDA designations that could expedite development, aiming to begin clinical studies in late 2024.
Read more →SCYX▲ +12%on this news
SCYNEXIS to Participate in September Investor Conferences
SCYNEXIS, Inc. announced its participation in two upcoming investor conferences in September 2023. The H.C. Wainwright 25th Annual Global Investment Conference will take place on September 12, followed by the Cantor Fitzgerald Global Healthcare Conference on September 28. The company continues to develop innovative antifungal medicines aimed at difficult-to-treat infections, underscoring its commitment to addressing drug resistance in this area.
Read more →SCYX▼ -6.4%on this news
SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update
SCYNEXIS reported significant advancements in its second quarter 2023 financial results, including a $90 million licensing agreement with GSK for ibrexafungerp. The company has achieved a $25 million development milestone related to its Phase 3 MARIO trial. Additionally, SCYNEXIS announced the acceptance of a New Drug Application for ibrexafungerp in China, aimed at treating vulvovaginal candidiasis. With a strong cash position, SCYNEXIS is well-positioned for continued growth and development of its antifungal therapies.
Read more →SCYX▲ +5.7%on this news
SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China
SCYNEXIS, Inc. announced that the National Medical Products Administration (NMPA) in China has accepted the New Drug Application (NDA) for ibrexafungerp, aimed at treating vulvovaginal candidiasis (VVC). The application was submitted by Hansoh Pharma and is based on positive Phase 3 trial results. The acceptance of the NDA signifies progress in the global fight against antifungal resistance, with ibrexafungerp positioned to provide a novel oral treatment option for patients. If approved, this would mark the first antifungal treatment of its kind available in China.
Read more →SCYXSCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK
SCYNEXIS, Inc. has achieved a significant $25 million milestone under its exclusive license agreement with GSK for ibrexafungerp, following development goals of the Phase 3 MARIO study focused on invasive candidiasis. This reflects the company's ongoing commitment to combating antifungal threats. The exclusive licensing agreement allows GSK to commercialize ibrexafungerp while SCYNEXIS is eligible for additional milestone payments totaling up to $503 million. Additionally, SCYNEXIS has already secured a total of $115 million through this agreement, enhancing its financial position.
Read more →SCYXSCYNEXIS to Participate in the Maxim Group Virtual Healthcare Conference
SCYNEXIS, Inc. will participate in the Maxim Group Virtual Healthcare Conference on June 20, 2023, with CEO David Angulo leading a fireside chat. The company is known for its innovative antifungal medicines, including BREXAFEMME® approved for treating vulvovaginal candidiasis and currently conducting late-stage investigations of ibrexafungerp for more severe fungal infections. This engagement showcases SCYNEXIS's commitment to advancing treatment for difficult-to-treat infections amid increasing drug resistance.
Read more →SCYXSCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME (Ibrexafungerp Tablets)
SCYNEXIS has finalized an exclusive license agreement with GSK for its antifungal product BREXAFEMME (ibrexafungerp tablets). This deal includes an upfront payment of $90 million, with additional milestone payments of up to $503 million. GSK will have the rights to commercialize BREXAFEMME in most regions, while SCYNEXIS retains rights to its other antifungal assets currently in development. This collaboration aims to address challenging fungal infections, especially in drug-resistant cases.
Read more →SCYXSCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update
SCYNEXIS announced significant financial results for Q1 2023, including an exclusive licensing agreement with GSK for the development of BREXAFEMME, entailing an upfront payment of $90 million and future performance-based milestones potentially totaling $503 million. The company reported a net loss of $33.9 million and decreased cash reserves from $73.5 million at the end of 2022. However, SCYNEXIS has a projected cash runway of more than two years, providing a stable financial outlook as it advances its clinical programs for ibrexafungerp, a novel antifungal treatment.
Read more →SCYXSCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark
SCYNEXIS, Inc. announced the presentation of interim data for ibrexafungerp at the 33rd Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Denmark. The presentation will cover findings from ongoing Phase 3 studies, including its use in treating urinary tract infections and invasive candidiasis. Ibrexafungerp is recognized as a novel antifungal agent with broad-spectrum efficacy against difficult-to-treat infections, especially those caused by drug-resistant pathogens.
Read more →SCYXSCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
SCYNEXIS has entered a significant exclusive agreement with GSK to commercialize and further develop its antifungal product BREXAFEMME (ibrexafungerp). This partnership will provide SCYNEXIS with an upfront payment of $90 million, along with potential future earnings from royalties and milestone payments. The company reported that enrollment is complete for key clinical trials demonstrating progress in treating serious fungal infections. However, despite some positive clinical data, the market for antifungals continues to be highly competitive, and SCYNEXIS must work to establish BREXAFEMME's presence in this landscape.
Read more →SCYX▼ -10.2%on this news· ran to -23% by day 3
SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis
BREXAFEMME, an oral, non-azole medication, is the first and only FDA-approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the reduction in the incidence of recurrent VVC. Approval is based on pivotal Phase 3 CANDLE data demonstrating statistically signif
Read more →SCYXSCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi
Researchers to study the potential of SCY-247 to fight Candida auris (C.auris), a multidrug-resistant pathogen named as an “urgent threat” by the Centers for Disease Control (CDC) and included in the “critital priority group” on the World Health Organization (WHO) fungal priority
Read more →SCYXSCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats
BARDA is seeking to support the development of broad-spectrum, oral/IV antifungal drug candidates with novel mechanisms of action that target Candida species, including Candida auris, and Aspergillus species. Ibrexafungerp, a first-in-class, broad-spectrum oral/IV antifungal mee
Read more →SCYX▼ -19.6%on this news
SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update • SCYNEXIS recently announced new strategic direction to refocus its resources on the clinical development of ibrexafungerp for s
SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update -SCYNEXIS recently announced new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications. -Ivor Macleod, a 30-year bioph
Read more →SCYXSCYNEXIS Announces Publication of Review Article Highlighting Ibrexafungerp as a Potential Novel Treatment for Invasive Mold Infections in the Journal of Fungi
JERSEY CITY, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced the publication of a review article highlig
Read more →SCYXSCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9
JERSEY CITY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at
Read more →SCYX▼ -7.1%on this news
SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022
Cumulative interim analysis of outcomes by fungal disease type highlighted in a platform presentation demonstrates 82.3% positive clinical outcomes in patients treated with ibrexafungerp. All-cause mortality analysis shows 94.6% survival 30 days post-therapy in patients with inv
Read more →SCYX▼ -15%on this newsshared move
SCYNEXIS Provides Corporate, Commercial and R&D Strategy Updates to Expand Market Potential for Its First-in-Class Antifungal
SCYNEXIS is announcing a new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications in which higher long-term returns are expected, given the promising data generated to date in refractory fungal infections
Read more →SCYXSCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022
JERSEY CITY, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that interim data from the Phase 3 FURI study of o
Read more →SCYXSCYNEXIS to Participate in Upcoming September Investor Conferences
JERSEY CITY, N.J., Sept. 09, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, President and Chief Executi
Read more →SCYXSCYNEXIS Presents Positive Interim Data of Ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study During the Mycoses Study Group Education and Research Consortium (MSGERC) Biennial Meeting
Approximately 83% of FURI patients with refractory Candida infections had positive clinical outcomes, defined as complete/partial response (56%) or no disease progression (27%). Data from the ongoing Phase 3 CARES study will also be presented demonstrating positive outcomes of i
Read more →SCYXSCYNEXIS to Present Posters Highlighting Ibrexafungerp Data at Four Upcoming Scientific Meetings in September 2022
JERSEY CITY, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will present posters at four upcoming U.S. and
Read more →SCYXSCYNEXIS Reports Second Quarter 2022 Financial Results and Provides Corporate Update BREXAFEMME (ibrexafungerp tablets) prescriptions in Q2 2022 increased 29 percent over Q1 2022, generating net revenues of $1.3 million
SCYNEXIS Reports Second Quarter 2022 Financial Results and Provides Corporate Update JERSEY CITY, N.J., August 15, 2022 - SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infecti
Read more →SCYX▼ -6.9%on this news
SCYNEXIS to Report Second Quarter 2022 Financial results and Provide a Corporate Update on August 15
JERSEY CITY, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at
Read more →SCYX▲ +8.7%on this newsshared move
SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting
The CANDLE study met its primary endpoint, with 65.4% of patients with recurrent vulvovaginal candidiasis (RVCC) who received monthly single-day ibrexafungerp treatment achieving clinical success with no recurrence at all, either culture-proven, presumed or suspected. Ibrexafung
Read more →SCYXSCYNEXIS Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME (ibrexafungerp tablets) for Prevention of Recurrent Vaginal Yeast Infections
Submission has been granted priority review and given a target regulatory decision date of November 30, 2022. If approved for this second indication, BREXAFEMME would be the first and only therapy approved in the U.S. for both the treatment of vulvovaginal candidiasis (VVC) and
Read more →SCYXSCYNEXIS Presents Positive Data from Phase 3 CANDLE Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the ISSVD XXVI World Congress and International Vulvovaginal Disease Update
Data show that 71% of 24 patients with recurrent vulvovaginal candidiasis (RVVC) who failed to respond to a three-day regimen of fluconazole achieved a substantial reduction or complete elimination of signs and symptoms after receiving a one-day treatment with ibrexafungerp. Dat
Read more →SCYXSCYNEXIS to Present Data from the CANDLE Nested Sub-Study of Ibrexafungerp During the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress and International Vulvovaginal Disease Update
JERSEY CITY, N.J., July 14, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that data from the CANDLE 304s nested sub-study of
Read more →SCYXSCYNEXIS Announces Initiation of New Phase 3b Study (VANQUISH) to Evaluate Oral Ibrexafungerp as a Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole
JERSEY CITY, N.J., June 23, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the initiation and first patient enrolled in a new
Read more →SCYXSCYNEXIS Announces Submission of Supplemental New Drug Application of BREXAFEMME (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections
Regulatory submission for the label extension is supported by positive data from the pivotal Phase 3 CANDLE study in which ibrexafungerp successfully achieved statistically significant superiority over placebo for the primary and key secondary study endpoints. If approved, BREXA
Read more →SCYXSCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
JERSEY CITY, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced grants of stock options to three new employ
Read more →SCYXSCYNEXIS to Present at Upcoming H.C. Wainwright Global Investment Conference
JERSEY CITY, N.J., May 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, President and Chief Executive
Read more →SCYXSCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update BREXAFEMME (ibrexafungerp tablets), launched in September 2021 for the treatment of vulvovaginal candidiasis (VVC), achieved almost 4,00
SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update JERSEY CITY, N.J., May 12, 2022 - SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections,
Read more →SCYXSCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
Data show that of the FURI study patients with refractory or relapsed vulvovaginal candidiasis (VVC) treated with ibrexafungerp, 71.4% had successful clinical outcomes. Ibrexafungerp demonstrated positive results in difficult-to-treat VVC patients with severe fungal infections w
Read more →SCYX▼ -6.9%on this news· ran to -24% by day 3shared move
SCYNEXIS to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12
JERSEY CITY, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at
Read more →SCYXSCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
JERSEY CITY, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, will present new data from its ongoing FURI study of ibrexafungerp
Read more →SCYXSCYNEXIS Presents Data Analyses Showing Ibrexafungerp’s Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases
New interim analysis of the Phase 3 CARES study showed complete or partial response in 78% of the 18 patients treated with ibrexafungerp for infections caused by Candida auris, a potentially deadly and multidrug-resistent pathogen with an outbreak recently reported at a Detroit s
Read more →SCYXSCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
JERSEY CITY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants were sold at a public offering price
Read more →SCYX▼ -25.8%on this newsshared move
SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections
Data reinforce findings from previous analyses demonstrating oral ibrexafungerp’s potential to combat difficult-to-treat and refractory fungal infections in the hospital setting. Ongoing FURI and CARES studies are a key component of the SCYNEXIS strategy to build ibrexafungerp i
Read more →SCYX▼ -25.8%on this newsshared move
SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
JERSEY CITY, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the pricing of its underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants are being sold at a public offering price of $3.00 per sh
Read more →SCYXSCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants
JERSEY CITY, N.J., April 21, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock, including pre-funded warrants to purchase c
Read more →SCYXSCYNEXIS to Present Positive Interim Data from Ongoing FURI and CARES Studies at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Being Held April 23-26 in Lisbon, Portugal
JERSEY CITY, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of interim data from its ongoing
Read more →SCYXSCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME (ibrexafungerp tablets), Providing Access to an Estimated 93 Million Commercially-Insured Lives
JERSEY CITY, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced that BREXAFEMME® (ibrexafungerp tablets) h
Read more →SCYXSCYNEXIS to Participate in Upcoming April Women’s Health Medical Conferences
JERSEY CITY, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced participation in three women’s health conferences
Read more →SCYX▼ -13%on this news
SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update BREXAFEMME (ibrexafungerp tablets), launched in August 2021, achieved net revenues of $1.1 million in 2021. Fourth quarte
SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update JERSEY CITY, N.J., March 29, 2022 - SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resi
Read more →SCYXSCYNEXIS to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update
JERSEY CITY, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, will announce fourth quarter and full year 2021 financial results
Read more →SCYXSCYNEXIS Named to Fast Company’s 2022 Top 50 List of the World’s Most Innovative Companies
JERSEY CITY, N.J., March 08, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it has been named to Fast Company’s annual list o
Read more →SCYXSCYNEXIS to Participate in Upcoming Scientific Conferences and Events
JERSEY CITY, N.J., March 02, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced its participation in three in-person medical conf
Read more →SCYXSCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022
Ibrexafungerp, the only fungicidal oral treatment for vaginal yeast infections, successfully achieved statistically significant superiority over placebo for the primary and key secondary study endpoints. SCYNEXIS will submit a supplemental New Drug Application (sNDA) for BREXAFE
Read more →SCYXSCYNEXIS to Participate in Upcoming January Investor Conferences
JERSEY CITY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, M.D., President and Chief Ex
Read more →SCYX▼ -9.6%on this news
SCYNEXIS Reports the Exercise of Warrants Totalling $21.1 Million
JERSEY CITY, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported the exercise of warrants to purchase 3.37 million s
Read more →SCYXSCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis
SCYNEXIS is initiating a global Phase 3 study to evaluate oral ibrexafungerp as a step-down treatment for invasive candidiasis (IC), including candidemia. Study provides an expeditious path toward approval of ibrexafungerp as the first non-azole oral therapy for invasive candidi
Read more →SCYXSCYNEXIS Reports the Exercise of Warrants Totalling $7.9 Million
JERSEY CITY, N.J., Dec. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported the exercise of warrants to purchase 1.2 million sh
Read more →SCYXSCYNEXIS to Host Ibrexafungerp Hospital Pipeline Update Call and KOL Webcast for Investors on December 6
JERSEY CITY, N.J., Nov. 29, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will host a hospital pipeline update for i
Read more →SCYX▲ +7.4%on this newsshared move
SCYNEXIS Pivotal Phase 3 VANISH-306 Trial Results Published in the International Journal of Obstetrics and Gynaecology (BJOG) Demonstrate Statistical Superiority of BREXAFEMME (Ibrexafungerp Tablets) Over Placebo for Vaginal Yeast Infection
Patients receiving one-day treatment with oral ibrexafungerp had significantly higher rates of clinical cure, mycological eradication, and clinical improvement at Day-10 compared to placebo-treated patients. Ibrexafungerp demonstrated sustained clinical effect at Day-25 follow-u
Read more →SCYXSCYNEXIS Reports Third Quarter 2021 Financial Results and Provides Corporate Update BREXAFEMME (ibrexafungerp tablets) net sales of $0.5 million generated since August, with IQVIA reporting 1,006 prescriptions in partial
SCYNEXIS Reports Third Quarter 2021 Financial Results and Provides Corporate Update JERSEY CITY, N.J., November 10, 2021 - SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infecti
Read more →SCYXSCYNEXIS Announces Successful Completion of Phase 1 Trial Evaluating Intravenous (IV) Formulation of Ibrexafungerp
JERSEY CITY, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the successful completion of a Phase 1 clinical st
Read more →SCYXSCYNEXIS to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 10
JERSEY CITY, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at
Read more →SCYXSCYNEXIS Pivotal Phase 3 VANISH-303 Trial Results Published in Clinical Infectious Diseases Demonstrate Significant Superiority of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection
In the Phase 3 VANISH-303 study, ibrexafungerp demonstrated significantly higher rates of clinical cure and infection eradication versus placebo. Post hoc analysis found ibrexafungerp demonstrated consistent efficacy in important patient sub-populations, characterized by race/et
Read more →SCYXSCYNEXIS to Present Pooled Data Analysis Results Demonstrating Consistent Efficacy and Safety Outcomes Across Two Phase 3 VANISH Clinical Trials of Oral Ibrexafungerp Therapy for Vaginal Yeast Infection at October Medical Conferences
JERSEY CITY, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced presentations of a pooled data analysis from its s
Read more →SCYXSCYNEXIS Announces Preclinical Data at the 10th Trends in Medical Mycology Meeting Supporting Potential of Ibrexafungerp to Treat Mucormycosis
In vivo data demonstrated response rate for ibrexafungerp similar to current standard of care options for the treatment of mucormycosis Combination of ibrexafungerp with current therapies showed significant enhancement in median survival time and overall survival when compared w
Read more →SCYXSCYNEXIS to Present Clinical Data from Ongoing FURI and CARES Studies at the 10th Trends in Medical Mycology Meeting Showing Oral Ibrexafungerp Provides a Favorable Therapeutic Response in Patients with Severe Fungal Infections
JERSEY CITY, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced two poster presentations of interim data from its
Read more →SCYXSCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek 2021 Showing Favorable Therapeutic Response in Severe Hospital-Based Fungal Infections Treated with Oral Ibrexafungerp
JERSEY CITY, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced an oral presentation of analyses of interim data
Read more →SCYXSCYNEXIS to Present Data on Oral Ibrexafungerp at IDWeek 2021 from Interim Analyses of Phase 3 FURI Clinical Trial Showing Therapeutic Response Rates in Patients with Mucocutaneous and Invasive Fungal Infections
JERSEY CITY, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced one oral and two poster presentations of interim
Read more →SCYXSCYNEXIS Announces U.S. Availability of BREXAFEMME (ibrexafungerp tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 Years
First and only oral non-azole treatment option approved for vaginal yeast infections is now available in pharmacies including cloud-based pharmacy New treatment is fungicidal against Candida species, disrupting the fungal cell wall and killing the fungi causing the infection, ra
Read more →SCYX▼ -7.7%on this news
SCYNEXIS Announces Hansoh Pharma’s Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)
JERSEY CITY, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Hansoh Pharmaceutical Group Company Limited
Read more →SCYXSCYNEXIS to Participate in Upcoming Investor Conferences
JERSEY CITY, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Company will participate in the followin
Read more →SCYXSCYNEXIS Reports Second Quarter 2021 Financial Results and Provides Corporate Update
BREXAFEMME® (ibrexafungerp tablets), the first novel antifungal class drug approved by the U.S. Food and Drug Administration (FDA) in more than 20 years, qualifies for 10 years of regulatory exclusivity and has 14 years of U.S. patent protection U.S. commercial launch of BREXAFE
Read more →SCYXSCYNEXIS Announces Two Oral Presentations on Pooled Data from the BREXAFEMME (Ibrexafungerp tablets) Phase 3 VANISH Program Demonstrating Consistent Efficacy in the Treatment for Vaginal Yeast Infections at the IDSOG 2021 Virtual Annual Meeting
The pooled data from two Phase 3 studies (VANISH-303 and VANISH-306) of one-day oral ibrexafungerp reflect a population that overwhelmingly had severe yeast infections, a condition typically treated with multiple doses of oral fluconazole Ibrexafungerp demonstrated consistent ef
Read more →SCYXSCYNEXIS Announces Three Oral Presentations of Ibrexafungerp Demonstrating Clinical and In Vitro Activity Against Candida Species at the 31st ECCMID
FURI and CARES presentations show ibrexafungerp’s strong clinical response in difficult-to-treat and refractory fungal infections in the hospital setting including Candida auris In vitro data demonstrates ibrexafungerp’s broad activity against 967 clinical Candida isolates from
Read more →SCYXSCYNEXIS to Present at Ladenburg Thalmann’s Virtual 2021 Healthcare Conference
JERSEY CITY, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Eric Francois, Chief Financial Officer, will
Read more →SCYXSCYNEXIS to Present Commercial Launch Update for BREXAFEMME (ibrexafungerp tablets)
BREXAFEMME, a one-day, novel, oral treatment for vaginal yeast infection, is the first FDA-approved indication of the ibrexafungerp antifungal development pipeline and the first approved drug from a novel antifungal class in over 20 years Commercial launch update call is schedul
Read more →SCYXSCYNEXIS to Present at the BIO Digital International Convention 2021
Company presentation will highlight BREXAFEMME® (ibrexafungerp tablets), the first FDA-approved product in the ibrexafungerp development pipeline, in addition to ongoing programs in the hospital setting JERSEY CITY, N.J., June 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:
Read more →SCYXSCYNEXIS Confirms that BREXAFEMME (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections
BREXAFEMME to receive 5-year exclusivity extension under the GAIN Act for a total of 10 years of regulatory exclusivity BREXAFEMME also protected by composition-of-matter patent until 2035 Commercial launch update call is scheduled for Tuesday, June 29th @ 12pm ET JERSEY CITY,
Read more →SCYXSCYNEXIS Announces FDA Approval of BREXAFEMME (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections
Approval of BREXAFEMME (ibrexafungerp) represents the first approved drug in a novel antifungal class in more than 20 years BREXAFEMME, a one-day oral treatment for vaginal yeast infection, is the first FDA-approved indication of the ibrexafungerp development pipeline U.S. comm
Read more →SCYXSCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update
Secured non-dilutive funding of approximately $35 million thus far in 2021, including licensing payments from Hansoh Pharma, the first tranche from a term loan agreement with Hercules and Silicon Valley Bank, and the monetization of the 2020 New Jersey NOLs Appointed Christine C
Read more →SCYXSCYNEXIS Secures Term Loan Facility for up to $60 Million with Hercules Capital and Silicon Valley Bank
Together with SCYNEXIS’ $93M cash balance at 12/31/20, the non-dilutive capital injections from this term loan, the recent licensing payments from Hansoh Pharma, and the monetization of 2020 New Jersey NOLs further strengthen SCYNEXIS’ balance sheet and projected cash runway into
Read more →SCYXSCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme Launch
Strengthening the management team with deep anti-infective commercial expertise across hospital and community settings ahead of anticipated approval of Brexafemme (ibrexafungerp) in June 2021 and H2:2021 launch JERSEY CITY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (
Read more →SCYXSCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme™) in Difficult-to-Treat Patients with Vaginal Yeast Infections
A single-day dose of oral ibrexafungerp demonstrates positive clinical outcomes in difficult-to-treat vulvovaginal candidiasis (VVC) patient populations: those with non-albicans Candida VVC and/or severe VVC Brexafemme, the expected trade name for ibrexafungerp, an oral antifung
Read more →SCYXSCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
FDA accepted SCYNEXIS’ New Drug Application (NDA) for oral ibrexafungerp for the treatment of vaginal yeast infections, conditionally approved the brand name BrexafemmeTM, and granted priority review with a PDUFA target action date of June 1, 2021 SCYNEXIS partnered with Amplity
Read more →SCYXSCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
Consistent with prior two interim analyses, FURI results confirm positive clinical activity of oral ibrexafungerp in patients with difficult-to-treat, severe, mucocutaneous and invasive fungal infections, including those caused by resistant strains 1st Interim analysis of CARES
Read more →SCYXSCYNEXIS to Participate in Maxim Group’s Late Stage Innovations in Women’s Health Virtual Event
JERSEY CITY, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, President and Chief Executiv
Read more →SCYXSCYNEXIS and Amplity Health Announce Agreement to Support the Anticipated U.S. Commercialization of BrexafemmeTM (Ibrexafungerp) for Vaginal Yeast Infections
Synergistic combination of Amplity’s proven commercial sales capabilities and SCYNEXIS’ internal medical, marketing, and strategic expertise will maximize Brexafemme’s commercial potential while preserving SCYNEXIS’ global rights to the drug Amplity to defer a portion of SCYNEXI
Read more →SCYXSCYNEXIS Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to Ibrexafungerp in Greater China
Hansoh Pharma, one of the largest biopharmaceutical companies in Greater China and in Asia, provides fully integrated R&D, manufacturing, and commercial capabilities to accelerate entry of ibrexafungerp in the global market SCYNEXIS to receive milestone payments of up to $122 mi
Read more →SCYXSCYNEXIS Announces Closing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
JERSEY CITY, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants were sold at a public offering price
Read more →SCYXSCYNEXIS Announces Pricing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
JERSEY CITY, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants are being sold at a public offering price of $6.25 per shar
Read more →SCYXSCYNEXIS Announces Launch of $50 Million Public Offering of Common Stock and Warrants
JERSEY CITY, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock, including pre-funded warrants to purchase com
Read more →SCYXSCYNEXIS Announces Advancement of Ibrexafungerp’s Intravenous Formulation to Clinical Stage and Provides Further Updates on its Clinical Studies in Patients with Life-Threatening Fungal Infections
Approval granted by health authority for the intravenous (IV) formulation of ibrexafungerp to enter Phase 1; dosing in healthy volunteers to start in the first quarter of 2021 New interim analysis of the data from the Phase 3 studies of ibrexafungerp in refractory invasive funga
Read more →SCYXSCYNEXIS Announces FDA Acceptance and Priority Review of New Drug Application for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infections
6-month Priority Review granted for ibrexafungerp with PDUFA target action date set for June 1, 2021 FDA indicated that it is not currently planning to hold an advisory committee meeting for the application SCYNEXIS is continuing preparations for a U.S. commercial launch of ibr
Read more →SCYXSCYNEXIS to Participate in Piper Sandler and Evercore ISI Conferences
JERSEY CITY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the Company’s participation in Piper Sandler’s 32n
Read more →SCYXSCYNEXIS Reports Third Quarter 2020 Financial Results and Provides Company Update
In October, SCYNEXIS submitted a New Drug Application (NDA) for ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) with expected approval in mid-2021. SCYNEXIS estimates that there are over 15 million antifungal prescriptions written each year for the treatment of
Read more →SCYXSCYNEXIS to Present Data Supporting the Efficacy of Ibrexafungerp Against Invasive Fungal Infections at IDWeek 2020
JERSEY CITY, N.J., Oct. 21, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it is presenting three posters on its late-st
Read more →SCYXSCYNEXIS Announces Submission of New Drug Application to the U.S. Food and Drug Administration for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infection
NDA submission is supported by positive data from two Phase 3 studies (VANISH Program) in women with vulvovaginal candidiasis (VVC) As a qualified infectious disease product (QIDP), ibrexafungerp is expected to receive a 6-month priority review following NDA acceptance JERSEY C
Read more →SCYXSCYNEXIS to Present Two Posters Highlighting Ibrexafungerp for the Treatment of Vaginal Yeast Infection at the 23rd Annual Premier Women's Healthcare Virtual Conference
JERSEY CITY, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of two posters at the Nurse Pract
Read more →SCYXSCYNEXIS to Participate in H.C. Wainwright Conference and Maxim’s Antifungal Webinar
JERSEY CITY, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Dr. Marco Taglietti, Chief Executive Officer
Read more →SCYXSCYNEXIS Announces Presentations at 2020 IDSOG Virtual Annual Meeting Highlighting Ibrexafungerp’s Potential for the Treatment of Vulvovaginal Candidiasis
Two oral presentations by VVC experts on ibrexafungerp, one in-vitro activity study and one on VANISH-303 study SCYNEXIS to sponsor symposium: “Current Challenges and Advancements in the Treatment of Vulvovaginal Candidiasis” JERSEY CITY, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) --
Read more →SCYXSCYNEXIS Reports Second Quarter 2020 Financial Results and Provides Company Update
In July, SCYNEXIS announced that it had successfully conducted pre-NDA meetings with the FDA regarding ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC) more commonly known as vaginal yeast infection. NDA submission for this indication remains on track for Q4 2020
Read more →SCYXSCYNEXIS Reports Successful Completion of Pre-NDA Meetings with the FDA Regarding Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis
Following recent productive meetings, the Company remains on track to submit a New Drug Application (NDA) for the treatment of Vulvovaginal Candidiasis (VVC), also known as Vaginal Yeast Infection, in Q4 2020. JERSEY CITY, N.J., July 29, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (
Read more →SCYXSCYNEXIS Announces Four Posters Presented at ASM Microbe 2020 Highlighting the Potential Clinical Utility of Ibrexafungerp
JERSEY CITY, N.J., July 22, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of four posters at the American S
Read more →SCYXSCYNEXIS Announces One-for-Ten Reverse Stock Split
JERSEY CITY, N.J., July 16, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ : SCYX) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of its issued and outstanding common stock, at
Read more →SCYXSCYNEXIS to Host A Key Opinion Leader Discussion on the Immediate Need in Treating Women with Vaginal Yeast Infections
Discussion will be conducted via Webcast Call on Tuesday, July 14th at 10am Eastern Time Event will highlight the impact of vaginal yeast infections on women, the shortcomings of existing treatments and the potential commercial opportunity for ibrexafungerp, SCYNEXIS’ novel anti
Read more →SCYXSCYNEXIS to Present at the BIO Digital International Convention 2020
Company presentation will highlight progress towards transitioning to a fully integrated commercial stage company with an initial focus on vaginal yeast infection JERSEY CITY, N.J., June 08, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneeri
Read more →SCYXSCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales
Appointment of seasoned women’s health marketing executive is a key step in the transition to a fully-integrated drug development and commercial company with initial focus on vaginal yeast infection JERSEY CITY, N.J., June 02, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCY
Read more →SCYXSCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update
In April, SCYNEXIS announced positive top-line results from the Phase 3 VANISH-306 study evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC), more commonly known as vaginal yeast infection. NDA submission for this indication is on track for the secon
Read more →SCYXSCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp
Oral ibrexafungerp continues to show potential to address a broad range of indications ranging from vaginal yeast infections to life-threatening refractory invasive fungal infections Findings indicate oral ibrexafungerp could potentially decrease length of hospital stays by redu
Read more →SCYXSCYNEXIS to Participate in Antifungals Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector
JERSEY CITY, N.J., April 28, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, M.D., President and Chief E
Read more →SCYXSCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection) Published
SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection) Published: Apr 21, 2020 JERSEY CITY, N.J., April 21, 2020 (GLOBE NEWSWIRE) SCYNEXIS, I
Read more →SCYXSCYNEXIS and Aspire Capital Enter into $20 Million Common Stock Purchase Agreement
SCYNEXIS has the ability, at its discretion, to efficiently access up to $20 million of capital $20 million purchase agreement, combined with $10 million cash injection from recent sale of convertible notes, affords additional financial flexibility and significantly strengthens
Read more →SCYXSCYNEXIS Secures $10 Million in Financing through Senior Convertible Note Purchase Agreement with Puissance Capital
JERSEY CITY, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the sale of its 6.0% Senior Convertible Notes due
Read more →SCYXSCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020
JERSEY CITY, N.J., March 26, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Dr. Nkechi Azie, SCYNEXIS’s VP of Clinical D
Read more →SCYXSCYNEXIS Reports Full Year 2019 Financial Results and Provides Company Update
Oral ibrexafungerp continues to advance in multiple indications Nearing completion of Phase 3 VANISH program, evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC), more commonly known as vaginal yeast infection; second of two studies (VANISH-306) has
Read more →SCYXSCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus Presented at the 9th Advances Against Aspergillosis and Mucormycosis Conference
Preclinical in vitro data showed synergistic activity against Aspergillus isolates from lung transplant recipients SCYNEXIS is conducting two clinical trials for patients suffering from Aspergillus infections: FURI evaluating ibrexafungerp as salvage therapy (alone or in combina
Read more →SCYXscyx-ex991_6.pptx.htm Corporate Presentation - Aug. 2018 Ibrexafungerp (formerly SCY-078) First Representative of a Novel Oral/IV Triterpenoid Antifungal Family "Committed to positively impacting the lives of patients su
Corporate Presentation - Aug. 2018 Ibrexafungerp (formerly SCY-078) First Representative of a Novel Oral/IV Triterpenoid Antifungal Family "Committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections" Forward-Lo
Read more →SCYXscyx-ex991_6.pptx.htm SCY-078 - First Representative of a Novel Oral/IV Triterpenoid Antifungal Family CORPORATE PRESENTATION | Mar. 2018 Certain statements regarding SCYNEXIS, Inc. (the "Company") made in this presentat
SCY-078 - First Representative of a Novel Oral/IV Triterpenoid Antifungal Family CORPORATE PRESENTATION | Mar. 2018 Certain statements regarding SCYNEXIS, Inc. (the "Company") made in this presentation constitute forward-looking statements, including, but not limited to, stateme
Read more →SCYXscyx-ex991_72.pptx.htm SCY-078 - First Representative of a Novel Oral/IV Triterpenoid Antifungal Family CORPORATE PRESENTATION | January 2018 Certain statements regarding SCYNEXIS, Inc. (the "Company") made in this prese
SCY-078 - First Representative of a Novel Oral/IV Triterpenoid Antifungal Family CORPORATE PRESENTATION | January 2018 Certain statements regarding SCYNEXIS, Inc. (the "Company") made in this presentation constitute forward-looking statements, including, but not limited to, stat
Read more →SCYXSCYNEXIS Presents New Data Further Supporting SCY-078 as a Potential Treatment for Aspergillus and Candida Infections at IDWeek 2017
JERSEY CITY, N.J., Oct. 05, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today presented new data for SCY-078, the Company’s lead product
Read more →SCYXSCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017
Additional SCY-078 Posters to be Presented at 8th Trends in Medical Mycology Pre-clinical data further highlight SCY-078’s broad spectrum of activity and differentiated attributes JERSEY CITY, N.J., Sept. 27, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnolog
Read more →SCYXSCYNEXIS to Present at Upcoming Investor Conferences
JERSEY CITY, N.J., Aug. 31, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the following u
Read more →SCYXSCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis Infections at the 2017 IDSOG Annual Meeting
Potent anti-Candida activity shown in vaginal acidic pH and high penetration into vaginal tissue Positive efficacy data reported from proof-of-concept Phase 2 VVC study JERSEY CITY, N.J., Aug. 14, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company de
Read more →SCYXSCYNEXIS Reports Second Quarter 2017 Financial Results and Provides Company Update
Dosing Initiated in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis Recent Data Publications Showcase Broad and Potent Activity of SCY-078 Against Multiple Fungal Species Including Candida auris JERSEY CITY, N.J., Aug. 08, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, In
Read more →SCYXSCYNEXIS to Present at the Canaccord Genuity Growth Conference
JERSEY CITY, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the Canaccord G
Read more →SCYXSCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis
Study initiation marks important milestone following promising clinical results in previous Phase 2 study Additional pre-clinical results for VVC to be presented at upcoming 2017 IDSOG Annual Meeting JERSEY CITY, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SC
Read more →SCYXSCYNEXIS, Inc. to Participate in the 2017 BIO International Convention
JERSEY CITY, N.J., June 13, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that Marco Taglietti, M.D., President and Chief
Read more →SCYXSCYNEXIS Reports First Quarter 2017 Financial Results and Provides Update on IV Formulation Development Status
JERSEY CITY, N.J., May 08, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the quarter ended March 31,
Read more →SCYXSCYNEXIS to Host a Conference Call to Discuss Lead Anti-Infective Candidate SCY-078 Data Presented at 27th ECCMID
JERSEY CITY, N.J., April 21, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that it will hold a conference call at 4:05 p.m
Read more →SCYXSCYNEXIS to Present SCY-078 Data on Novel Lead Anti-infective Candidate at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Oral presentation of Phase 2 study discusses oral SCY-078 in patients with invasive candidiasis Potent in vitro activity of SCY-078 against multidrug-resistant fungal pathogen Candida auris In vitro synergy of SCY-078 in combination with other antifungals against Aspergillus A
Read more →SCYXSCYNEXIS, Inc. to Present at the 16th Annual Needham Healthcare Conference
JERSEY CITY, N.J., March 29, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs, today announced that the Company will present
Read more →SCYXSCYNEXIS Reports Full Year 2016 Financial Results and Provides Company Update
JERSEY CITY, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs, today reported financial results for the year
Read more →SCYXSCYNEXIS, Inc. to Present at the 29th Annual ROTH Conference
JERSEY CITY, N.J., March 07, 2017 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the 29th Annual ROTH Conference at the Ritz Carlton Laguna Niguel in Dana Point on Tuesday, March 14, 2017 at 5:30 p.m. PT.
Read more →SCYXSCYNEXIS delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA’s request
JERSEY CITY, N.J., March 02, 2017 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the United States Food and Drug Administration (FDA) has informed the Company to hold the initiation of any new clinical studies with the intravenous (
Read more →SCYXSCYNEXIS, Inc. to Participate in Upcoming Investor Conferences
JERSEY CITY, N.J., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will participate in the following upcoming investor conferences: Canaccord Genuity Rare Disease Conference at the InterContinental New York
Read more →SCYXSCYNEXIS Announces Appointment of Industry Veteran Marion McCourt to its Board of Directors
— Former Chief Operating Officer of Medivation adds broad experience in commercial, strategy, operations and business development — — SCYNEXIS to ramp up commercial preparatory and territorial licensing activities for its lead product, SCY-078 — JERSEY CITY, N.J., Jan. 26, 2017
Read more →SCYXSCYNEXIS Achieves New Development Milestones Reinforcing the Versatility of SCY-078 in Treating Serious Fungal Infections
– Regimen of intravenous (IV) formulation of SCY-078 successfully identified and characterized to support subsequent studies – – Long-term toxicology studies completed, confirming favorable safety profile of oral SCY-078 – JERSEY CITY, N.J., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Dr
Read more →SCYXSCYNEXIS, Inc. to Participate in the Guggenheim Securities 4th Annual Boston Healthcare Conference
JERSEY CITY, N.J., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX), a pharmaceutical company developing novel anti-infectives to address unmet therapeutic needs, today announced that the Company will participate in the Guggenheim Securities
Read more →SCYXSCYNEXIS, Inc. Reports Third Quarter 2016 Financial Results and Provides Company Update
-- Positive Results From Multiple Studies Provide Clear Evidence of Clinical Antifungal Activity and Favorable Safety Profile of SCY-078 -- -- Company is Well Positioned and Capitalized to Accelerate and Expand Clinical Development of SCY-078 in Multiple Indications -- JERSEY C
Read more →SCYXSCYNEXIS Completes Two Additional Clinical Studies Further Supporting the Favorable Safety Profile of SCY-078
SCY-078 demonstrates a low potential for certain drug-drug interactions – a relevant differentiator versus the azoles, the leading antifungal class – providing an opportunity for favorable labeling Significant step forward to further de-risk the ongoing development program of SC
Read more →SCYXSCYNEXIS Announces Complete Results from Two Phase 2 Studies of Oral SCY-078 in Patients with Candida spp. Infections and Closing of a $15 Million Term Loan
Study Results Confirm Overall Antifungal Activity of Oral SCY-078 in Patients with Candida Infections Well-Tolerated and Active Oral Dose of SCY-078 Identified for Invasive Candidiasis Patients Evidence of Efficacy and Lower Relapse Rates versus Standard of Care in VVC Patients
Read more →SCYXSCYNEXIS, Inc. to Present at the Ladenburg Thalmann Healthcare Conference
JERSEY CITY, N.J., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference at the Sofitel New York Hotel on Tuesday, September 27, 2016 at 3:00 p.m. ET.
Read more →SCYXSCYNEXIS, Inc. to Present at Upcoming Investor Conferences
JERSEY CITY, N.J., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the following upcoming investor conferences: The Baird Global Healthcare Conference at the New York Palace Hotel on Wednesd
Read more →SCYXSCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Aspergillus Infections
JERSEY CITY, N.J., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company’s novel triterpenoid broad-spectrum antifungal agent, SCY
Read more →SCYXSCYNEXIS, Inc. Reports Second Quarter 2016 Financial Results and Provides Company Update
Positive Results from Two Phase 2 Studies Confirm Antifungal Clinical Activity of SCY-078 Company is Well Positioned and Capitalized to Advance its Clinical Programs Forward As Planned JERSEY CITY, N.J., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc.
Read more →SCYXSCYNEXIS, Inc. to Present at the Canaccord Genuity Growth Conference
JERSEY CITY, N.J., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Canaccord Genuity Growth Conference at the InterContinental Boston on Thursday, August 11, 2016 at 2:00 p.m. ET. A live
Read more →SCYXSCYNEXIS Announces Interim Results from Phase 2 Study of Oral SCY-078 in Patients with Invasive Candidiasis
Oral Dose of SCY-078 That Achieves Target Exposure Identified SCY-078 Safe and Well-Tolerated Antifungal Clinical Activity of SCY-078 Further Confirmed JERSEY CITY, N.J., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced th
Read more →SCYXSCYNEXIS, Inc. Announces Sale of Cyclophilin Inhibitor Assets to Cypralis Limited
JERSEY CITY, N.J., July 13, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the Company has entered into an Asset Purchase agreement with UK-based Cypralis Limited, a life sciences company focused on the discovery of novel thera
Read more →SCYXSCYNEXIS, Inc. to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
JERSEY CITY, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference at Le Parker Meridien New York on Tuesday, July 12, 2016 at 9:00 a.m. E
Read more →SCYXSCYNEXIS Announces Pricing of $22.5 Million Public Offering of Common Stock and Warrants
JERSEY CITY, N.J., June 21, 2016 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of 9,375,000 shares of its common stock and warrants to purchase 4,218,750 shares of its common stock. The shares and warrants are bei
Read more →SCYXSCYNEXIS Inc. Presents New Clinical and Non-Clinical Data Confirming the Potential of SCY-078 as a Novel Treatment for Life-threatening Fungal Infections
SCY-078 shown to be the first glucan synthase inhibitor with high oral bioavailability in humans Fungicidal activity of SCY-078 demonstrated against multiple Candida species, including difficult-to-treat strains SCY-078 progressing to next stages of clinical development in inva
Read more →SCYXSCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at ASM Microbe 2016
JERSEY CITY, N.J., June 10, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that results of one Phase 1 study and one nonclinical study of the company’s lead clinical drug candidate, SCY-078, will be presented in podium presentations
Read more →SCYXSCYNEXIS, Inc. Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors
Confirmation of Clinically Relevant Antifungal Activity of SCY-078 in Patients with Candida Infections Company to Host a Conference Call Today at 5:00pm ET to Discuss Results JERSEY CITY, N.J., June 08, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SC
Read more →SCYXSCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Candida Infections
JERSEY CITY, N.J., May 13, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company’s novel and structurally distinct glucan synthase inhibito
Read more →SCYXSCYNEXIS, Inc. Reports First Quarter 2016 Financial Results and Provides Company Update
JERSEY CITY, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the quarter ended March 31, 2016, and provided an update on recent operational and clinical developments. “The clinical development prog
Read more →SCYXSCYNEXIS Receives Designation as a Small and Medium Enterprise by the European Medicines Agency
JERSEY CITY, N.J., April 19, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that the Company has been granted Small and Medium Sized Enterprise (SME) status by the European Medicines Agency (EMA). The SME designation was created by
Read more →SCYXSCYNEXIS Presents Data Supporting the Activity of its Lead Antifungal Drug Candidate SCY-078 Against Antifungal-resistant Candida Strains at the 13th ASM Conference on Candida and Candidiasis
JERSEY CITY, N.J., April 15, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that results of three nonclinical studies of the company’s lead clinical drug candidate, SCY-078, were presented at the 13th American Society for Microbiolo
Read more →SCYXSCYNEXIS, Inc. to Present at the 15th Annual Needham Healthcare Conference
JERSEY CITY, N.J., April 06, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the 15th Annual Needham Healthcare Conference at The Westin Grand Central Hotel in New York City on Wednesday, April 13, 20
Read more →SCYXSCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at 13th ASM Conference on Candida and Candidiasis
JERSEY CITY, N.J., April 06, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that results of three nonclinical studies of the company’s lead clinical drug candidate, SCY-078, will be presented in poster presentations at the 13th Amer
Read more →SCYXSCYNEXIS, Inc. Reports Full Year 2015 Financial Results and Provides Company Update
JERSEY CITY, N.J., March 07, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the year ended December 31, 2015, and provided an update on recent operational and clinical developments. "2015 was an important trans
Read more →SCYXSCYNEXIS, Inc. to Present at the Cowen and Company 36th Annual Health Care Conference
JERSEY CITY, N.J., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Cowen and Company 36th Annual Health Care Conference at the Boston Marriott Copley Place in Boston on Monday, March 7, 2
Read more →SCYXSCYNEXIS, Inc. Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections
JERSEY CITY, N.J., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track and Qualified Infectious Disease Product (QIDP) designations for the intravenous
Read more →SCYXSCYNEXIS, Inc. Initiates Enrollment of the Phase 2 Study of SCY-078 in Vulvovaginal Candidiasis
JERSEY CITY, N.J., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has initiated enrollment and the first group of patients have been dosed in its Phase 2 study of oral SCY-078 as a treatment for vulvovaginal candidia
Read more →SCYXSCYNEXIS, Inc. Reports Third Quarter 2015 Financial Results and Provides Company Update
JERSEY CITY, N.J., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the quarter ended September 30, 2015, and provided an update on recent operational and clinical developments. "We have made significant
Read more →SCYXSCYNEXIS, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating Intravenous Formulation of SCY-078
JERSEY CITY, N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the initiation of a Phase 1 clinical trial to study the intravenous (IV) formulation of SCY-078. SCYNEXIS' novel antifungal drug candidate SCY-078 is in deve
Read more →SCYXSCYNEXIS Appoints Eric Francois as Chief Financial Officer
JERSEY CITY, N.J., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the appointment of Eric Francois as Chief Financial Officer, effective immediately. Mr. Francois will be responsible for the Company's corporate
Read more →SCYXEMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT ( " Agreement " ) , effecti v e a s o f
EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT ("Agreement"), effective as of November 1, 2015 (the "Effective Date"), is by and between SCYNEXIS, Inc., a Delaware corporation ("Employer" or "Company") and Eric Francois ("Employee"). WHEREAS, Employer considers the availability
Read more →SCYXto Form 8-K, the fair value of the warrants issued in connection with our Series D-2 Preferred offering in January 2014 was $0.4 million above the face amount of the Series D-2 Preferred. This excess was expensed in the
Operating results for the year ended December 31, 2014, are not necessarily indicative of results that may occur in future interim periods or future fiscal years. Some of the statements in this "Management's Discussion and Analysis of Financial Condition and Results of Operations
Read more →SCYXSCYNEXIS Appoints Rajeshwar Motheram as Vice President, Pharmaceutical Development
- Strengthens Management Team with the Addition of Pharmaceutical Development Expertise - - Announces Inducement Grant Under NASDAQ Rule 5635(c)(4) - JERSEY CITY, N.J., Oct. 7, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today an
Read more →SCYXSCYNEXIS, Inc. Announces Board of Directors Transitions
JERSEY CITY, N.J., Sept. 28, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the following changes to its Board of Directors: Edward E. Penhoet, Ph.D., has stepped down from the Board of Directors; and C. Patrick Mach
Read more →SCYXSCYNEXIS Presents Data Supporting the Potential Clinical Utility of Antifungal Drug Candidate at ICAAC/ICC 2015
JERSEY CITY, N.J., Sept. 21, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced today that results of three nonclinical studies of the company's lead clinical drug candidate, SCY-078, were presented in podium and poster presenta
Read more →SCYXSCYNEXIS to Present Data at ICAAC/ICC 2015 for Novel Antifungal Drug Candidate
JERSEY CITY, N.J., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced one podium and three poster presentations related to non-clinical studies of the Company's lead clinical drug candidate, SCY-078. The data wil
Read more →SCYXSCYNEXIS, Inc. Reports Second Quarter 2015 Financial Results
RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the second quarter of 2015. "In reflecting on the first quarter and subsequent period of my tenure as CEO at S
Read more →SCYXSCYNEXIS, Inc. to Present at 35th Canaccord Genuity Annual Growth Conference
RESEARCH TRIANGLE PARK, N.C., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that Marco Taglietti, M.D., SCYNEXIS' Chief Executive Officer, will present at the 35th Canaccord Genuity Annual Growth Conference at the InterCon
Read more →SCYXUNAUDITED CONDENSED PRO FORMA FINANCIAL STATEMENTS As disclosed within the Current Report on Form 8-K accompanying this exhibit, we have completed the sale of our contract research and development services business (the
UNAUDITED CONDENSED PRO FORMA FINANCIAL STATEMENTS As disclosed within the Current Report on Form 8-K accompanying this exhibit, we have completed the sale of our contract research and development services business (the Service Business ). The unaudited pro forma financial inf
Read more →SCYXSCYNEXIS, Inc. to Focus on SCY-078 Development
RESEARCH TRIANGLE PARK, N.C., July 23, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has completed an asset purchase agreement with Avista Pharma Solutions for the sale of its contract research and development
Read more →SCYXSCYNEXIS, Inc. to Present at 10th Annual JMP Securities Life Sciences Conference
RESEARCH TRIANGLE PARK, N.C., June 18, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that David Angulo, M.D., SCYNEXIS' Chief Medical Officer, will present at the 10th Annual JMP Securities Life Sciences Conference at
Read more →SCYXSCYNEXIS, Inc. Announces Changes to Board of Directors
RESEARCH TRIANGLE PARK, N.C., June 10, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the following changes to its Board of Directors: Guy Macdonald has been appointed Chairman of the Board of Directors, effective as
Read more →SCYXSCYNEXIS, Inc. Announces New Employment Inducement Grant
RESEARCH TRIANGLE PARK, N.C., June 5, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that on June 4, 2015, new employee David Angulo, M.D., the company's Chief Medical Officer, was granted an option to purchase 125,000
Read more →SCYXSCYNEXIS, Inc. to Present at Jefferies 2015 Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., May 26, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that Marco Taglietti, M.D., SCYNEXIS' Chief Executive Officer, will present at the Jefferies 2015 Healthcare Conference at the Grand
Read more →SCYXSCYNEXIS, Inc. Reports First Quarter 2015 Financial Results
RESEARCH TRIANGLE PARK, N.C., May 15, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the first quarter of 2015. "We are in a strong financial position following the successful completion of our fo
Read more →SCYXSCYNEXIS Appoints David Angulo, M.D., as Chief Medical Officer
RESEARCH TRIANGLE PARK, N.C., May 14, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the appointment of David Angulo, M.D., as Chief Medical Officer, effective June 1, 2015. Dr. Angulo will be responsible for advancing
Read more →SCYXSCYNEXIS Announces Pricing of Public Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C., April 22, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of 4,675,324 shares of its common stock at a public offering price of $7.70 per sha
Read more →SCYXSCYNEXIS Announces Launch of Public Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C., April 20, 2015 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the commencement of an underwritten public offering of shares of its common stock and expects to raise gross proceeds of up to $30 million. The company expects to grant t
Read more →SCYXSCYNEXIS, Inc. UNAUDITED PRO FORMA CONDENSED FINANCIAL STATEMENTS As disclosed in our Annual Report on Form 10-K for the year ended
UNAUDITED PRO FORMA CONDENSED FINANCIAL STATEMENTS As disclosed in our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the Securities and Exchange Commission, or SEC, on March 30, 2015, we are currently exploring the divestiture of our contract resea
Read more →SCYXSCYNEXIS, Inc. Reports Full Year 2014 Financial Results
RESEARCH TRIANGLE PARK, N.C., March 30, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the year ended December 31, 2014. "This year was an important year for us in the evolution of the Company, as
Read more →SCYXSCYNEXIS, Inc. to Present at Jefferies 2015 Antibiotic Summit
RESEARCH TRIANGLE PARK, N.C., March 12, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that members of the SCYNEXIS executive management team will present at the Jefferies 2015 Antibiotic Summit hosted by Eun Yang at t
Read more →SCYXSCYNEXIS, Inc. Appoints Steven C. Gilman, Ph.D., to Board of Directors
RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2015 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the appointment of Steven C. Gilman, Ph.D., to its Board of Directors. Dr. Gilman most recently served as the Executive Vice President, Research & Development and Chief Sc
Read more →SCYXSCYNEXIS, Inc. to Present at RBC Capital Markets 2015 Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that Yves J. Ribeill, Ph.D., SCYNEXIS' CEO and President, will present at the RBC Capital Markets 2015 Healthcare Conference at the
Read more →SCYXSCYNEXIS Names Marco Taglietti, M.D., Chief Executive Officer
Yves Ribeill, Ph.D., to Remain President, Serve on Board of Directors Carole Sable, M.D., Submits Resignation as Chief Medical Officer RESEARCH TRIANGLE PARK, N.C., Feb. 6, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) announced to
Read more →SCYXSCYNEXIS, Inc. January 2015 1 Certain statements regarding SCYNEXIS, Inc. (the "Company") made in this presentation may constitute forward-looking statements, including, but not limited to, statements regarding our busin
SCYNEXIS, Inc. January 2015 1 Certain statements regarding SCYNEXIS, Inc. (the "Company") made in this presentation may constitute forward-looking statements, including, but not limited to, statements regarding our business strategies and goals, plans and prospects, market size,
Read more →SCYXSCYNEXIS, Inc. Receives FDA Fast Track Designation for Oral Formulation of SCY-078 for the Treatment of Patients With Invasive Fungal Infections
RESEARCH TRIANGLE PARK, N.C., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation for the oral formulation of SCY-078, the Company's
Read more →SCYXSCYNEXIS, Inc. Announces Appointment of Two Seasoned Industry Professionals to Its Board of Directors
RESEARCH TRIANGLE PARK, N.C., Dec. 3, 2014 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the appointment of Guy Macdonald and Marco Taglietti, M.D., to its Board of Directors. Mr. Macdonald currently serves as President and Chief Executive Officer of Tetraphase
Read more →SCYXSCYNEXIS, Inc. Reports Third Quarter 2014 Financial Results
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the third quarter ended September 30, 2014. "This quarter we've taken two important steps forward in the devel
Read more →SCYXSCYNEXIS, Inc. Enters Into Worldwide Agreement With Waterstone Pharmaceutical for the Development and Commercialization of SCY-635 for Viral Diseases
RESEARCH TRIANGLE PARK, N.C., Nov. 3, 2014 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that they have entered into a license agreement granting Waterstone Pharmaceutical (HK) Limited, an international pharmaceutical company with its main operations in China,
Read more →SCYXSCYNEXIS, Inc. Reports Second Quarter 2014 Financial Results
RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today reported financial results for the second quarter ended June 30, 2014. "The completion of our initial public offering this past quarter was a
Read more →SCYXSCYNEXIS, Inc. to Present at Canaccord Genuity Growth Conference 2014
RESEARCH TRIANGLE PARK, N.C., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that Yves J. Ribeill, Ph.D., SCYNEXIS' President and Chief Executive Officer, will present at the Canaccord Genuity Growth Conference
Read more →SCYXSCYNEXIS, Inc. (Nasdaq:SCYX) to Ring The NASDAQ Stock Market Closing Bell
ADVISORY, June 27, 2014 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX), a drug discovery and development company, will visit the NASDAQ MarketSite in Times Square to commemorate the successful closing of its initial public offering. In honor of the occasion, Yves J. Ribeill,
Read more →SCYXSCYNEXIS, Inc. to Present at JMP Securities Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., June 18, 2014 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that Yves J. Ribeill, Ph.D., SCYNEXIS' President and Chief Executive Officer, will present at the 9th Annual JMP Securities Healthca
Read more →SCYXSCYNEXIS Provides Update on Corporate Progress and First Quarter 2014 Financial Results
RESEARCH TRIANGLE PARK, N.C., June 16, 2014 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX), a clinical-stage company focused on developing novel anti-infectives to address drug-resistant infections, today provided a corporate progress update and reported financial results for t
Read more →SCYXSCYNEXIS Appoints Vivian Doelling as Vice President of Animal Health
RESEARCH TRIANGLE PARK, NC--(Marketwired - Nov 20, 2013) - Drug discovery company SCYNEXIS, Inc. today announced the appointment of Dr. Vivian Doelling as Vice President of Animal Health. Doelling is an industry leader in the field of animal health with more than 20 years of expe
Read more →SCYXSCYNEXIS Signs Deal With R-Pharm to Develop and Market Novel Antifungal Compound in Russia and Other Markets
MOSCOW, RUSSIA and RESEARCH TRIANGLE PARK, NC--(Marketwired - Sep 10, 2013) - Drug discovery company SCYNEXIS, Inc. and R-Pharm today announced that they have entered into an agreement granting R-Pharm exclusive rights to develop and commercialize SCY-078 in Russia and several ot
Read more →SCYXSCYNEXIS Gains Worldwide Rights to Novel Antifungal Compound
RESEARCH TRIANGLE PARK, NC--(Marketwired - May 29, 2013) - SCYNEXIS, Inc. announced today that Merck, known as MSD outside the United States and Canada, has decided to return to SCYNEXIS all development and commercialization rights for the novel antifungal compound MK-3118, an or
Read more →SCYXSCYNEXIS and Immune Design Collaborate on Innovative Process for Vaccine Production Technology
RESEARCH TRIANGLE PARK, NC--(Marketwired - Apr 10, 2013) - SCYNEXIS, Inc. announced today that Immune Design Corp. has selected SCYNEXIS as its chemical development and cGMP production partner for manufacture of Glucopyranosyl Lipid A (GLA). Immune Design's GLA is the first clin
Read more →SCYXSCYNEXIS to Present on Screening Technology Used in Anti-Malarial Research at ACS National Meeting
RESEARCH TRIANGLE PARK, NC--(Marketwire - Aug 20, 2012) - SCYNEXIS, Inc. announces the presentation of innovative screening approaches used in the discovery of promising anti-malarial therapies at the American Chemical Society's (ACS) national meeting. Paul J. Kowalczyk, Ph.D.,
Read more →SCYXSCYNEXIS and TB Alliance Sign HEOS Software Agreement
RESEARCH TRIANGLE PARK, NC--(Marketwire - Jun 16, 2011) - Drug discovery company SCYNEXIS, Inc. announced today that it has signed an agreement that provides TB Alliance with access to SCYNEXIS' proprietary HEOS® drug discovery software platform for use in the organization's glob
Read more →SCYXSCYNEXIS Introduces Application for Mobile Access to HEOS Information System
RESEARCH TRIANGLE PARK, NC--(Marketwire - November 10, 2010) - Drug discovery and development company SCYNEXIS announced today the development of an iPhone application to allow mobile access to the company's HEOS web-based SaaS drug research information management software. The
Read more →SCYXSCYNEXIS Receives Merial Research Collaboration Milestone Payment
RESEARCH TRIANGLE PARK, NC--(Marketwire - November 9, 2010) - Merial Limited and SCYNEXIS, Inc. announced today that SCYNEXIS has earned a fourth payment for meeting certain milestones in a multi-year research collaboration which began in 2005. SCYNEXIS, a premier drug discovery
Read more →SCYXSCYNEXIS Announces Presentations of Data From Anti-Fungal Drug Candidate at the 50th ICAAC Meeting
RESEARCH TRIANGLE PARK, NC--(Marketwire - September 14, 2010) - Drug discovery company, SCYNEXIS, Inc. today announced that one oral presentation and five posters related to its collaboration with Merck & Co. to develop novel antifungal agents are being presented at the 50th Inte
Read more →SCYXSCYNEXIS and Trevena Announce Strategic Collaboration to Enhance Discovery of Biased GPCR Ligands
RESEARCH TRIANGLE PARK, NC and KING OF PRUSSIA, PA--(Marketwire - May 19, 2010) - SCYNEXIS, Inc., a drug discovery and development company, and Trevena, Inc., a leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today that they
Read more →SCYXSCYNEXIS, Inc. Receives Milestone Payment From Collaboration With Merck Co., Inc.
RESEARCH TRIANGLE PARK, NC--(Marketwire - December 17, 2009) - Drug discovery and development company SCYNEXIS, Inc. announced today that it has achieved a third milestone in its collaboration with Merck & Co., Inc. to develop novel antifungal agents. This latest milestone pay
Read more →SCYXSCYNEXIS cGMP Facilities Audited by FDA -- No Form 483 Observations Issued
RESEARCH TRIANGLE PARK, NC--(Marketwire - December 16, 2009) - SCYNEXIS, Inc., a fully-integrated drug discovery and development company, today announced that the U.S. Food and Drug Administration (FDA) completed its cGMP compliance inspection of the SCYNEXIS Process Chemistry
Read more →SCYXSCYNEXIS and DNDi Extend Collaboration to Identify Drug Candidates to Treat Sleeping Sickness
RESEARCH TRIANGLE PARK, NC and GENEVA--(Marketwire - December 11, 2008) - SCYNEXIS, Inc. and Drugs for Neglected Diseases initiative (DNDi) announced today that they have extended their collaboration on vital drug discovery research and development of affordable and effective
Read more →SCYXSCYNEXIS und DNDi setzen Kooperation zur Identifizierung von Wirkstoffkandidaten zur Behandlung der Schlafkrankheit fort
RESEARCH TRIANGLE PARK, North Carolina, und GENF--(Marketwire - December 11, 2008) - SCYNEXIS, Inc. und DNDi (Drugs for Neglected Diseases initiative) gaben heute bekannt, dass die beiden Organisationen ihre Kooperation f r die Erforschung und Entwicklung vitaler, erschwingliche
Read more →SCYXSCYNEXIS, Inc. Completes $13.5 Million Financing
RESEARCH TRIANGLE PARK, NC--(Marketwire - March 27, 2008) - SCYNEXIS, Inc., a premier drug discovery and development company, today announced the successful completion of a $13.5 million Series C-2 financing. The financing was led by Merial Limited, a joint venture between Mer
Read more →SCYXSCYNEXIS to Present at the JPMorgan Healthcare Conference on January 8, 2008
RESEARCH TRIANGLE PARK, NC--(Marketwire - January 7, 2008) - SCYNEXIS, Inc. announced today its participation in the 26th Annual JPMorgan Healthcare Conference, January 7-10, 2008 at the Westin St. Francis Hotel in San Francisco. Yves J. Ribeill, Ph.D., President and CEO, will
Read more →SCYXSCYNEXIS and DNDi Enter Landmark Multi-Year Agreement to Identify Drug Candidates to Treat Sleeping Sickness
RESEARCH TRIANGLE PARK, NC and GENEVA, SWITZERLAND--(Marketwire - November 5, 2007) - SCYNEXIS and Drugs for Neglected Diseases initiative (DNDi) have agreed to collaborate on vital drug discovery research and development of affordable and effective therapies for human African
Read more →SCYXSCYNEXIS, Inc. Receives Preclinical Milestone Payment in Collaboration With Merck
RESEARCH TRIANGLE PARK, NC -- (MARKET WIRE) -- January 9, 2007 --SCYNEXIS, Inc. today announced that it has earned a $1 million payment from Merck & Co., Inc. for meeting certain preclinical milestones in the companies' collaboration to develop novel antifungal agents. "Merck
Read more →SCYXSCYNEXIS Announces Research Agreement With Merck for Discovery of Novel Oncology Agents
RESEARCH TRIANGLE PARK, NC -- (MARKET WIRE) -- December 6, 2006 --SCYNEXIS, Inc., a chemistry-focused drug discovery and development company, today announced that it has entered into a multi-year research agreement with Merck & Co., Inc. to discover and develop novel oncology
Read more →Competitive Position
How SCYX ranks across every disease it competes inCompetitive Position is a premium feature
See how SCYX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial